Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 3/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.39 |
| ▸ | CKS1B | P61024 | 11/20 | 0.38 |
| ▸ | SKP1 | P63208 | 11/20 | 0.38 |
| ▸ | SKP2 | Q13309 | 11/20 | 0.38 |
| ▸ | SMO | Q99835 | 3/20 | 0.36 |
| ▸ | NPY2R | P49146 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | ACACA | Q13085 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20071856 | 0.90 | NR1H2 (0.48) | NR1H2NR1H3CKS1BSKP1SKP2 | |
| SCHEMBL23824830 | 0.90 | NR1H2 (0.48) | NR1H2NR1H3CKS1BSKP1SKP2 | |
| SCHEMBL21686301 | 0.90 | NR1H2 (0.48) | NR1H2NR1H3CKS1BSKP1SKP2 | |
| SCHEMBL23824834 | 0.90 | NR1H2 (0.48) | NR1H2NR1H3CKS1BSKP1SKP2 | |
| SCHEMBL21686314 | 0.86 | NR1H2 (0.40) | NR1H2NR1H3SMONPY2R | |
| SCHEMBL21686266 | 0.85 | NR1H2 (0.57) | NR1H2NR1H3NPY2R | |
| SCHEMBL23838210 | 0.83 | NR1H2 (0.43) | NR1H2NR1H3CKS1BSKP1SKP2 | |
| SCHEMBL21644334 | 0.83 | SMO (0.35) | NR1H2NR1H3SMO | |
| SCHEMBL21644148 | 0.82 | NR1H2 (0.41) | NR1H2NR1H3 | |
| SCHEMBL20071862 | 0.82 | NR1H2 (0.41) | NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10961215-B2 | N-aryl and N-heteroaryl piperidine derivatives as liver X receptor beta agonists, compositions, and their use | MERCK SHARP & DOHME CORP. (US) | 2021-03-30 | — | — | US | disclosed |
| US-20200039951-A1 | N-ARYL AND N-HETEROARYL PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039951-A1 | N-ARYL AND N-HETEROARYL PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE | NR1H2, NR1H3, NR1H4 | NR1H2 1/4885NR1H3 2/4885CKS1B 2960/4885 |
| US-10961215-B2 | N-aryl and N-heteroaryl piperidine derivatives as liver X receptor beta agonists, compositions, and their use | NR1H2, NR1H3, NR1H4 | NR1H2 1/4885NR1H3 2/4885CKS1B 2960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.